SECONDARY PREVENTION IN SMALL SUBCORTICAL STROKES (SPS3)

小皮质下中风的二级预防 (SPS3)

基本信息

项目摘要

Small subcortical strokes (S3), also known as lacunar infarcts, comprise nearly 25 percent of brain infarcts, are harbingers of vascular dementia, and are particularly frequent in Mexican- Americans. Combination antiplatelet therapy using clopidogrel plus aspirin and intensive lowering of blood pressure could substantially reduce major vascular events and cognitive decline in S3 patients. However, a large randomized clinical trial is required to define the efficacy and safety of these interventions specifically in patients with S3 due to presumed small vessel disease. This proposal is for a pilot study to: 1. Determine the lowest tolerable, achievable target blood pressures among survivors of S3. 2. To assess whether the difference between the lowest tolerable blood pressures are sufficiently different from that achieved by standard targets to substantially impact the occurrence of subsequent stroke and cognitive decline. 3. To quantitatively assess white matter abnormalities in S3 patient by serial MRI, correlating these with patient features, cognitive status, blood pressure control and antiplatelet treatment. 4. To assess the relationship of Mexican-American ethnicity to blood pressure interventions, tolerance of antiplatelet therapy, extent and progression of white matter abnormalities, and cognitive status, as well as to modify and assess existing screening tests of cognitive status for those who primarily speak Spanish. Participants with S3 attributed to small vessel disease will be randomized to treatment with aspirin (650mg/d) or aspirin plus clopidogrel (75mg/d) (double-blind), while those with a history of hypertension will additionally be randomized to three different target levels of blood pressure lowering (not blinded). The tolerance and achieved blood pressures in each target level will be the primary outcome, with tolerance and side-effects of antiplatelet therapy also assessed. Quantitative MRI will be done at entry and after a mean of one year, correlated with cognitive status, interventions and ethnicity. No clinical trials have assessed secondary prevention in S3, the most common type of stroke in Mexican Americans and accounting for about 150,000 strokes yearly in the US. While this pilot study is a necessary first-step for a larger, definitive clinical trial, valuable and unique information about blood pressure control after stroke and about issues relevant to stroke prevention in Mexican-Americans will emerge.
皮质下小卒中(S3),也称为腔隙性脑梗死,占脑梗死的近25%,是血管性痴呆的先兆,在墨西哥裔美国人中尤其常见。 使用氯吡格雷加阿司匹林的联合抗血小板治疗和强化降压可显著减少S3患者的主要血管事件和认知功能下降。 然而,需要进行一项大型随机临床试验来确定这些干预措施的有效性和安全性,特别是在假定的小血管疾病导致的S3患者中。本提案是一项试点研究,目的是:1.确定S3幸存者的最低可耐受、可达到的目标血压。 2.评估最低可耐受血压之间的差异是否与标准目标所达到的差异有足够大的差异,以显著影响后续卒中和认知能力下降的发生。 3.通过系列MRI定量评估S3患者的白色异常,并将其与患者特征、认知状态、血压控制和抗血小板治疗相关联。 4.评估墨西哥裔美国人种族与血压干预、抗血小板治疗耐受性、白色物质异常的程度和进展以及认知状态的关系,以及修改和评估主要讲西班牙语的人群的认知状态的现有筛查测试。小血管疾病导致的S3受试者将随机接受阿司匹林(650 mg/d)或阿司匹林+氯吡格雷(75 mg/d)治疗(双盲),而有高血压病史的受试者将额外随机接受三种不同的降压目标水平(非盲)。每个目标水平的耐受性和达到的血压将是主要结局,还评估了抗血小板治疗的耐受性和副作用。 将在入组时和平均一年后进行定量MRI,与认知状态、干预措施和种族相关。没有临床试验评估S3的二级预防,S3是墨西哥裔美国人最常见的中风类型,在美国每年约有15万例中风。 虽然这项试点研究是一个更大的,明确的临床试验的必要的第一步,有价值的和独特的信息,中风后的血压控制和有关的问题,中风预防在墨西哥裔美国人将出现。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Left Ventricular Geometry on Transthoracic Echocardiogram and Prognosis after Lacunar Stroke: The SPS3 Trial.
经胸超声心动图的左心室几何形状和腔隙性卒中后的预后:SPS3 试验。
Small vessel strokes.
  • DOI:
    10.1007/s11886-005-0006-6
  • 发表时间:
    2005-01-01
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Benavente, Oscar;White, Carole L;Roldan, Ana M
  • 通讯作者:
    Roldan, Ana M
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial.
小皮质下中风二级预防 (SPS3) 试验的 3020 名参与者的临床特征和种族/民族差异。
Antithrombotic therapy in small subcortical strokes (lacunar infarcts).
小型皮质下中风(腔隙性梗塞)的抗血栓治疗。
  • DOI:
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Benavente,Oscar
  • 通讯作者:
    Benavente,Oscar
Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial.
  • DOI:
    10.1016/s1474-4422(14)70224-8
  • 发表时间:
    2014-12
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Pearce LA;McClure LA;Anderson DC;Jacova C;Sharma M;Hart RG;Benavente OR;SPS3 Investigators
  • 通讯作者:
    SPS3 Investigators
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OSCAR R BENAVENTE其他文献

OSCAR R BENAVENTE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OSCAR R BENAVENTE', 18)}}的其他基金

Secondary Prevention of Subcortical Stroke Prevention Genetic Substudy
皮质下中风预防的二级预防基因亚组研究
  • 批准号:
    8239529
  • 财政年份:
    2011
  • 资助金额:
    $ 48.74万
  • 项目类别:
Secondary Prevention of Subcortical Stroke Prevention Genetic Substudy
皮质下中风预防的二级预防基因亚组研究
  • 批准号:
    8064133
  • 财政年份:
    2011
  • 资助金额:
    $ 48.74万
  • 项目类别:
Secondary Prevention of Subcortical Stroke Prevention Genetic Substudy
皮质下中风预防的二级预防基因亚组研究
  • 批准号:
    8436282
  • 财政年份:
    2011
  • 资助金额:
    $ 48.74万
  • 项目类别:
SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPSS)
小皮质下中风的二级预防 (SPSS)
  • 批准号:
    7696316
  • 财政年份:
    2008
  • 资助金额:
    $ 48.74万
  • 项目类别:
SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)
小皮质下中风的二级预防 (SPS3)
  • 批准号:
    7211467
  • 财政年份:
    1999
  • 资助金额:
    $ 48.74万
  • 项目类别:
SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)
小皮质下中风的二级预防 (SPS3)
  • 批准号:
    6849321
  • 财政年份:
    1999
  • 资助金额:
    $ 48.74万
  • 项目类别:
SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)
小皮质下中风的二级预防 (SPS3)
  • 批准号:
    8184784
  • 财政年份:
    1999
  • 资助金额:
    $ 48.74万
  • 项目类别:
SECONDARY PREVENTION IN SMALL SUBCORTICAL STROKES (SPS3)
小皮质下中风的二级预防 (SPS3)
  • 批准号:
    2832067
  • 财政年份:
    1999
  • 资助金额:
    $ 48.74万
  • 项目类别:
SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)
小皮质下中风的二级预防 (SPS3)
  • 批准号:
    8069957
  • 财政年份:
    1999
  • 资助金额:
    $ 48.74万
  • 项目类别:
SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)
小皮质下中风的二级预防 (SPS3)
  • 批准号:
    6806209
  • 财政年份:
    1999
  • 资助金额:
    $ 48.74万
  • 项目类别:

相似国自然基金

Aspirin调控AKT/Foxo3a/BIM通路延缓吡咯替尼耐药作用机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
Aspirin与自噬通路及核转录因子FoxG1在听觉系统退行性变中的协同调控机制研究
  • 批准号:
    81800915
  • 批准年份:
    2018
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
Aspirin联合牙周膜干细胞再生全脱位牙牙周组织机制研究
  • 批准号:
    81760190
  • 批准年份:
    2017
  • 资助金额:
    32.0 万元
  • 项目类别:
    地区科学基金项目
可注射温敏型水凝胶缓释Aspirin碳点和EPO促牙周组织再生的研究
  • 批准号:
    81600879
  • 批准年份:
    2016
  • 资助金额:
    17.0 万元
  • 项目类别:
    青年科学基金项目
Aspirin协同IFN-α抑制肝癌转移复发的作用及机制研究
  • 批准号:
    30972889
  • 批准年份:
    2009
  • 资助金额:
    31.0 万元
  • 项目类别:
    面上项目
胃癌microRNA特异表达与靶基因调控及Aspirin的作用
  • 批准号:
    30873099
  • 批准年份:
    2008
  • 资助金额:
    35.0 万元
  • 项目类别:
    面上项目

相似海外基金

Postpartum low-dose aspirin to augment vascular recovery following a hypertensive disorder of pregnancy
产后小剂量阿司匹林可促进妊娠高血压疾病后的血管恢复
  • 批准号:
    10644089
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events
阿司匹林、Lp(a) 和心血管事件的一级预防
  • 批准号:
    10720757
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
早期双倍低剂量阿司匹林减少先兆子痫和流产:全球方法随机对照试验
  • 批准号:
    10711793
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)
阿司匹林用于脂蛋白升高患者心血管疾病的一级预防(a)
  • 批准号:
    10739016
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial
PARTUM(产后阿司匹林减少血栓栓塞过度发病率)试验
  • 批准号:
    498295
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Operating Grants
Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias
患有阿尔茨海默病和相关痴呆症的老年人停用阿司匹林的健康结果
  • 批准号:
    10662129
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
A study on the use of aspirin mini tablets for children with Kawasaki disease for the practical application of mini tablets
阿司匹林迷你片在川崎病患儿中的应用研究
  • 批准号:
    23K16462
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Is Aspirin a Cost-Effective Thromboprophylaxis Alternative for Orthopaedic Trauma Patients?
阿司匹林是骨科创伤患者经济有效的血栓预防替代方案吗?
  • 批准号:
    10784156
  • 财政年份:
    2023
  • 资助金额:
    $ 48.74万
  • 项目类别:
Aspirin and severe maternal morbidity and mortality and adverse pregnancy outcomes
阿司匹林与严重孕产妇发病率和死亡率以及不良妊娠结局
  • 批准号:
    469014
  • 财政年份:
    2022
  • 资助金额:
    $ 48.74万
  • 项目类别:
    Operating Grants
Effects of inflammaging on intestinal epithelial cells and aspirin chemoprevention.
炎症对肠上皮细胞的影响和阿司匹林化学预防。
  • 批准号:
    10152090
  • 财政年份:
    2021
  • 资助金额:
    $ 48.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了